2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 499

Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic
Abstract Number: 2036

Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with RA
Abstract Number: 115

Biologic Dmards Modify the Association Between Patient Expectations and Outcomes of Total Knee Replacement in Rheumatoid Arthritis Patients
Abstract Number: 2300

Biologic Treatment in Systemic Juvenile Idiopathic Arthritis: Single Center Experience
Abstract Number: 280

Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Abstract Number: 2514

Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
Abstract Number: 811

Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Abstract Number: 911

Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-Kb-Mediated Inflammation
Abstract Number: 630

Biomarkers of Bone Remodeling Are Elevated in Psoriatic Arthritis
Abstract Number: 373

Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis
Abstract Number: 629

Biomarkers of Chondrocyte Activity Are Increased in Psoriasis Arthritis and Spondyloarthritis
Abstract Number: 808

Biomarkers of Disease Activity in Vasculitis
Abstract Number: 1652

Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus
Abstract Number: 1866

Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Abstract Number: 831

Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].